Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Argenta and Pcovery Announce Drug Discovery Collaboration

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
Under the terms of the agreement, Argenta will provide medicinal chemistry and computer-aided drug design services to assist Pcovery.

Argenta announces that it has signed a collaboration agreement with Pcovery. The collaboration is funded by a Wellcome Trust Seeding Drug Discovery (SDD) award.

According to the US Centers for Disease Control and Prevention*, mycotic (fungal) infections pose a growing threat to public health. Opportunistic infections such as cryptococcosis and aspergillosis are becoming increasingly problematic due to the rising number of people with weakened immune systems, such as cancer patients, transplant recipients, and people with HIV/AIDS. In addition, hospital-associated infections such as candidemia are a leading cause of bloodstream infections in the United States and advances and changes in healthcare practices can provide opportunities for new and drug-resistant fungi to emerge in hospital settings. Finally, community-acquired infections such as coccidioidomycosis (valley fever), blastomycosis, and histoplasmosis are caused by fungi that are abundant in the environment and whose prevalence may be being increased by climate change. Consequently, there is a need for novel anti-fungal agents that can tackle threats such as these.

Pcovery is focused on the development of safe and efficient broad-spectrum anti-fungal agents using structure-based drug discovery to target membrane proteins. Pcovery is a spin-out company from the PUMPkin Centre (Centre for Membrane Pumps in Cells and Disease) at Aarhus University and Copenhagen University and was established in April 2009. The company’s investors include Novo Seeds and Østjysk Innovation.

Dr John Montana, Managing Director of Argenta, commented, “Argenta is pleased to announce this collaboration with Pcovery, which represents the third Wellcome Trust SDD-funded project aided by Argenta during the funding rounds in 2012. The Argenta team looks forward to working with Pcovery towards achieving the project goals over the coming months”.

Mr Casper Tind Hansen, CEO of Pcovery says, “We look forward very much to working with the highly skilled and capable Argenta team to progress what will hopefully be a novel class of anti-fungal drugs for invasive fungal infections. The Argenta team has already been a big help in securing the Wellcome Trust SDD funding.” 

*US Centers for Disease Control and Prevention website, http://www.cdc.gov/fungal/, accessed 14 May 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Argenta Expands Collaboration with Genentech to Include BioFocus
Under the amendment, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.
Thursday, September 16, 2010
Argenta Discovery Announces Two-Year Extension of Major Drug Discovery Collaboration with Genentech
This is the second extension of the contract drug discovery agreement since the first collaboration was announced in December 2005.
Friday, May 22, 2009
Scientific News
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Space Research Fighting Cancer
JPL and National Cancer Institute renew Big Data partnership that 'learns' data similarities.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Manipulation of Liquid Crystals Could Help Control Drug-Delivery Process
Computer modeling, real-world testing yields new method.
A New Approach for Deciphering Complex Immune Responses
Study seeks to establish the parameters that characterize the immune system of healthy individuals and its natural variability.
Infectious Prion Structure Shines Light on BSE
Prion research useing electron cryomicroscopy technology identified the structure of the infectious prion protein that causes BSE.
Vaccination Strategies Coax HIV-Neutralizing Antibody Production
New approaches to encourage the human immune system to produce HIV-blocking antibodies have been successful in mice.
Sequencing Soviet Anthrax
Next-gen genomic analysis has generated an anthrax genome sequence formerly from the USSR’s biological weapons program.
Closer to ‘Flesh-Eating’ Bacteria Vaccine
Patterns uncovered in the outer protein coat of group A Strep could lead to a vaccine againt the bacteria.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!